2023 Annual Meeting | Industry Therapeutic Update from Eisai: Alzheimer’s Disease: Preparing for a Shift in the Treatment Landscape

Date Saturday 04/22/23

Time 06:00 PM - 09:00 PM EST Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Sharon Cohen, MD, Lawrence S. Honig, MD, PhD, FAAN, Darren R. Gitelman, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Clinical experts in the field of Alzheimers disease (AD) will provide their insights on the evolving diagnostic and treatment landscape. Faculty will offer their perspectives on the patients journey through the discussion of several topics including: changes in the diagnostic workflow utilizing traditional and novel clinical tools; diagnosing appropriate real-world patients based on biomarkers; clinical considerations for potential treatment shifts; and managing patient expectations, and appropriate monitoring. Additionally, this session will provide case-based examples of patient profiles. Overall, this session aims to provide perspective to neurologists that may be helpful for the clinical management of patients with AD and assist in adoption of new treatment landscapes. Sponsored by Eisai Inc. Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2023 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
06:00 PM - 09:00 PM EST	Speaker	Industry Therapeutic Update from Eisai: Alzheimer’s Disease: Preparing for a Shift in the Treatment Landscape

Faculty Disclosures
Sharon Cohen, MD	Dr. Cohen has nothing to disclose.
Lawrence S. Honig, MD, PhD, FAAN	Dr. Honig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Honig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Honig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Honig has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail. Dr. Honig has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cortexyme. Dr. Honig has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Legal Firms . The institution of Dr. Honig has received research support from Roche. The institution of Dr. Honig has received research support from Eisau. Dr. Honig has received research support from Alector. The institution of Dr. Honig has received research support from Transposon.
Darren R. Gitelman, MD, FAAN	The institution of an immediate family member of Dr. Gitelman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astra Zeneca. The institution of Dr. Gitelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. The institution of Dr. Gitelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Gitelman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. The institution of Dr. Gitelman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. An immediate family member of Dr. Gitelman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of an immediate family member of Dr. Gitelman has received research support from Pfizer. The institution of an immediate family member of Dr. Gitelman has received research support from UCB. The institution of Dr. Gitelman has received research support from Biogen. The institution of Dr. Gitelman has received research support from Eisai. The institution of Dr. Gitelman has received research support from Lilly. The institution of Dr. Gitelman has received research support from Cassava. The institution of Dr. Gitelman has received research support from Wake Forest / Alzheimer's Association / NIH. The institution of Dr. Gitelman has received research support from Davos Alzheimer's Collaborative. The institution of Dr. Gitelman has received research support from Bristol Myers Squibb. An immediate family member of Dr. Gitelman has a non-compensated relationship as a Advisory Committee with Food and Drug Administration that is relevant to AAN interests or activities.

��ɫ��

��ɫ��